Flupirtine: A review of its neuroprotective and behavioral properties

CNS Drug Reviews

Volumn 4, Issue 2, 1998, Pages 149-164

  Schuster, G ^a   Schwarz, M ^b   Block, F ^b   Pergande, G ^c   Schmidt, W J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c ASTA MEDICA AG   (Germany)

Author keywords

Ca2+ homeostasis; Flupirtine; Muscle relaxation; Neuroprotection; NMDA receptor; Parkinson's disease

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ADENOSINE TRIPHOSPHATE; BRIMONIDINE; CLONIDINE; DIZOCILPINE; DNA FRAGMENT; FLUPIRTINE; GLUTATHIONE; LEVODOPA; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; PROTEIN BCL 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BEHAVIOR; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NERVE CELL; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; RETINA ISCHEMIA; REVIEW;

EID: 0032453746     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00061.x     Document Type: Review

References (50)

1. Bebenburg W, Thiele K, Engel J, Sheldrick WS. Synthese und Molekülstruktur des konstitutionell neuartigen Analgetikums Flupirtin. Chem Ztg 1981;105:217-219.
2. Block F, Schwarz M, Sontag KH. Retinal ischemia induced by occlusion of both common carotid arteries in rats as demonstrated by electroretinography. Neurosci Lett 1992;144:124-126.
3. Block F, Pergande G, Schwarz M. Flupirtine protects against ischemic retinal dysfunction in rats. NeuroReport 1994;5:2630-2632.
4. Block F, Pergande G, Schwarz M. Flupirtine reduces functional and morphological consequences induced by global ischemia in rats. Brain Res 1997;754:279-284.
5. Block F, Schwarz M. The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol 1998;30:281-287.
6. Bredesen DE. Neuronal apoptosis: Genetic and biochemical modulation. In: Thomei LD, Cope FD, eds., Apoptosis II: The molecular basis of apoptosis in disease. Cold Spring Harbour, New York: Cold Spring Harbour Laboratory Press, 1994:397-421.
7. Friedel HA, Fitton A. Flupirtine: A review of its pharmacological properties on therapeutic efficacy in pain states. Drugs 1993;45:548-569.
8. Gozlan H, Ben Ari Y. NMDA receptor redox sites: Are they targets for selective neuronal protection? Trends Pharmacol Sci 1995;16:368-374.
9. Herrmann WM, Hiersemenzl R, Aigner M, et al. Die Langzeitverträglichkeit von Flupirtin. Offene multizentrische Studie über ein Jahr. Fortschr Med 1993;266-270.
10. Hlavica P, Niebch G. Untersuchungen zur Pharmakokinetik und Biotransformation des Analgetikums Flupirtin beim Menschen. Drug Res 1985;35:42-49.
11. Jakovlev V, Sofia RD, Achteratz-Truckermann U, von Schlichtegroll A, Thiemer K. Untersuchungen zur pharmakologischen Wirkung von Flupirtin, einem strukturell neuartigen Analgetikum. Drug Res 1985;35:5-18.
12. Kretschmer BD, Bubser M, Schmidt WJ. Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur J Pharmacol 1995;280:37-45.
13. Lipton S, Choi YB, Sucher NJ, Pan ZH, Stamler JS. Redox state, NMDA receptors, and NO-related species. Trends Pharmacol Sci 1996;17:187-189.
14. McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994;74:723-760.
15. Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984;9:204-212.
16. Moore R, Bullingham RES, Simpson S, O'Sullivan G, Evans PJD, McQuay J. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983;55:429-432.
17. Müller WEG, Pergande G, Ushijima H, Schleger C, Kelve M, Perovic S. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog Mol Subcell Biol 1996;16:44-57.
18. Müller WEG, Romero FJ, Pergande G, Perovic S. Flupirtine: A neuroprotective agent against β-amyloid-induced apoptosis in vitro. Brain Res 1996;37:575-577.
19. Müller WEG, Romero FJ, Perovic S, Pergande G, Pialoglou P. Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro: Prevention of amyloid-induced glutathione depletion. J Neurochem 1997;68:2371-2377.
20. Müller WEG, Dobmeyer JM, Dobmeyer TS, et al. Flupirtine protects both neuronal cells and lymphocytes against induced apoptosis in vitro: Implications for treatment of AIDS patients. Cell Death Differ 1997;4:51-58.
21. Müller-Limroth W. Einfluß des neuen Analgetikums Flupirtin auf die psychomotorische Leistungsfähigkeit des Menschen. Drug Res 1985;35:1089-1092.
22. Nickel B, Jakovlev V, Szelenyi I. Effects of flupirtine, some analgesics, and muscle relaxants on skeletal muscle tone in conscious rats. Arzneim-Forsch/Drug Res 1990;40:909-911.
23. Nickel B, Herz A, Jakovlev V, Tibes U. Studies of the mode of action of the analgesic agent flupirtine. Drug Res 1985;35:1402-1409.
24. Obermeier K, Niebch G, Thiemer K. Investigations on the pharmacokinetics and biotransformation of the analgesic flupirtine in rat and dog. Drug Res 1985;35:60-67.
25. Osborne NN, Herrera AJ. The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivity in the rabbit retina. Neuroscience 1994;59:1071-1081.
26. Osborne NN, Pergande G, Block F, Schwarz M. Immunohistochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid-induced release of GABA in the rabbit retina. Brain Res 1994;667:291-294.
27. Osborne NN, Schwarz M, Pergande G. Protection of rabbit retina from ischemic injury by flupirtine. Invest Ophthalmol Vis Sci 1996;37:274-280.
28. Osborne NN, Cazevieille C, Pergande G, Wood JP. Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Invest Ophthalmol Vis Sci 1997;38:1390-1400.
29. Osborne NN, Cazevieille C, Wood JPM, et al. Flupirtine, a non-opioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol 1998;30:255-263.
30. Perovic S, Schleger C, Pergande G, et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol 1994;288:27-33.
31. Perovic S, Pergande G, Ushijima H, Kelve M, Forrest J, Müller WEG. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 1995;4:369-374.
32. Perovic S, Pialoglou P, Romero FJ, Pergande G, Müller WEG. Flupirtine increases the levels of glutathione and Bcl-2 in hNT neurons: Mode of action of the drug-mediated antiapoptotic effect. Eur J Pharmacol 1996;317:157-164.
33. Perovic S, Schröder HC, Pergande G, Ushijima H, Müller WEG. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997;147:518-524.
34. 2+ concentration. Eur J Pharmacol 1995;294:469-473.
35. Schmidt WJ. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 1986;90:123-130.
36. Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997;327:1-9.
37. Schwarz M, Block F, Pergande G. N-methyl-D-aspartate (NMDA) mediated muscle relaxant action of flupirtine in rats. NeuroReport 1994;5:1981-1984.
38. Schwarz M, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm 1996;103:581-590.
39. 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995;276:247-255.
40. Seaman CA, Sheridan PH, Engel J, Moliere M, Narang PK, Nice FJ. Flupirtine. In: Meldrum BS, Porter RJ, eds., New Anticonvulsant Drugs. London: Libbey, 135-145.
41. Sofia RD, Diamantis W, Gordon R. Abuse potential and physical dependence liability studies with flupirtine maleate in laboratory animals. Postgrad Med J 1987;63(Suppl 3):35-40.
42. Swedberg MDB, Shannon HE, Nickel B, Goldberg SR. Pharmacological mechanisms of action of flupirtine: A novel, centrally acting, nonopioid analgesic evaluated by discriminative effects in the rat. J Pharmacol Exp Therap 1988;246:1067-1074.
43. Szelenyi I, Nickel B. Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug. Agents Actions 1991;32(Suppl):119-123.
44. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989;97:835-842.
45. Timmann D, Plummer C, Schwarz M, Diener HC. Influence of flupirtine on human lower limb reflexes. Electroenceph Clin Neurophysiol 1995;97:184-188.
46. Watkins JC, Collingridge GL. The NMDA receptor. Oxford, UK: Oxford University Press, 1989.
47. Weiser T, Nickel B, Szelenyi I, Wienrich M. In vivo and in vitro about the muscle relaxing properties of flupirtine. Autumn Meeting of the German Society for the Study of Pain, November 4-7, Bielefeld, Germany, 1992.
48. Wörz R, Bolten W, Heller B, Krainick JU, Pergande G. Flupirtin im Vergleich zu Chlormezanon und Placebo bei chronischen muskuloskelettalen Rückenschmerzen. Fortschr Med 1996;35/36:3-7.
49. 2+ uptake and ATP synthesis in mitochondria. Br J Pharmacol 1998;123:1154-1158.
50. Zhong LT, Sarafian T, Kane DJ, et al. Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 1993;90:4533-4537.